dehydroepiandrosterone has been researched along with Syndrome in 23 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)." | 9.27 | Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; BSc, AB; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2018) |
| "The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)." | 9.22 | Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; Beauregard, A; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2016) |
| " To understand the influence of hormones on schizophrenia symptoms, serum steroids (estradiol, progesterone, follicular stimulating hormone (FSH), luteinising hormone (LH), and dehydroepiandrosterone (DHEA)) and psychopathology (The positive-and-negative-syndrome-scale(PANSS)) and depression (Montgomery-Asberg-Depression-Rating Scale(MADRS)) were collected across 12-weeks in 45 women (mean age 46) diagnosed with schizophrenia." | 5.30 | Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia. ( Gavrilidis, E; Gurvich, C; Hudaib, AR; Kulkarni, J; Thomas, N, 2019) |
| "The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)." | 5.27 | Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; BSc, AB; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2018) |
| "The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)." | 5.22 | Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; Beauregard, A; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2016) |
| " More recently, double-blind, placebo-controlled clinical trials have demonstrated that local vaginal dehydroepiandrosterone improves symptoms in postmenopausal women, including moderate to severe dyspareunia." | 3.88 | The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. ( Archer, DF; Bachmann, G; Davis, SR; Goldstein, AT; Goldstein, I; Kellogg-Spadt, S; Kim, NN; Lowenstein, L; Nappi, RE; Pinkerton, JV; Simon, JA; Stuenkel, CA; Traish, AM; Vignozzi, L, 2018) |
| "Ospemifene therapy was however superior to laser and vaginal estrogen therapies in ameliorating sexual function, however, it presents a high risk of developing adverse events and endometrial hyperplasia." | 2.72 | Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients. ( Chang, Y; Duan, H; Li, B; Wang, S, 2021) |
| "Patients with breast cancer receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively known as genitourinary syndrome of menopause (GSM)." | 2.61 | Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy. ( Abraham, J; Kruse, ML; Sussman, TA; Thacker, HL, 2019) |
| "The syndrome was perceived as new, and various explanations were advanced such as factitious disorder, intoxication, or stress." | 1.38 | Patterns of endogenous steroids in apathetic refugee children are compatible with long-term stress. ( Aronsson, B; Bergquist, J; Kushnir, MM; Sandstedt, P; Söndergaard, HP, 2012) |
| "Their insulin resistance was significantly greater than that in a control group with comparable obesity." | 1.27 | Obesity, acanthosis nigricans, insulin resistance, and hyperandrogenemia: pediatric perspective and natural history. ( Cavallo, A; Meyer, WJ; Peters, EJ; Prince, MJ; Richards, GE; Smith, ER; Stuart, CA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (39.13) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Stute, P | 1 |
| Bertschy, S | 1 |
| Birkhaeuser, M | 1 |
| Bitzer, J | 1 |
| Ging, A | 1 |
| Raggi, A | 1 |
| Steimann, S | 1 |
| Stute, V | 1 |
| Salvatore, S | 3 |
| Benini, V | 3 |
| Ruffolo, AF | 3 |
| Degliuomini, RS | 3 |
| Redaelli, A | 3 |
| Casiraghi, A | 3 |
| Candiani, M | 3 |
| Thomas, N | 1 |
| Gurvich, C | 1 |
| Hudaib, AR | 1 |
| Gavrilidis, E | 1 |
| Kulkarni, J | 1 |
| Li, B | 1 |
| Duan, H | 1 |
| Chang, Y | 1 |
| Wang, S | 1 |
| Simon, JA | 1 |
| Goldstein, I | 1 |
| Kim, NN | 1 |
| Davis, SR | 1 |
| Kellogg-Spadt, S | 1 |
| Lowenstein, L | 1 |
| Pinkerton, JV | 1 |
| Stuenkel, CA | 1 |
| Traish, AM | 1 |
| Archer, DF | 3 |
| Bachmann, G | 1 |
| Goldstein, AT | 1 |
| Nappi, RE | 1 |
| Vignozzi, L | 1 |
| Labrie, F | 2 |
| Koltun, W | 2 |
| Vachon, A | 2 |
| Young, D | 2 |
| Frenette, L | 2 |
| Portman, D | 2 |
| Montesino, M | 2 |
| Côté, I | 2 |
| Parent, J | 2 |
| Lavoie, L | 2 |
| BSc, AB | 1 |
| Martel, C | 2 |
| Vaillancourt, M | 2 |
| Balser, J | 2 |
| Moyneur, É | 2 |
| Yoshihara, T | 1 |
| Ozaki, H | 1 |
| Nakagata, T | 1 |
| Natsume, T | 1 |
| Kitada, T | 1 |
| Ishihara, Y | 1 |
| Sawada, S | 1 |
| Ishibashi, M | 1 |
| Kobayashi, H | 1 |
| Machida, S | 1 |
| Naito, H | 1 |
| Sussman, TA | 1 |
| Kruse, ML | 1 |
| Thacker, HL | 1 |
| Abraham, J | 1 |
| Samaras, N | 1 |
| Samaras, D | 1 |
| Frangos, E | 1 |
| Forster, A | 1 |
| Philippe, J | 1 |
| Beauregard, A | 1 |
| Gandhi, J | 1 |
| Chen, A | 1 |
| Dagur, G | 1 |
| Suh, Y | 1 |
| Smith, N | 1 |
| Cali, B | 1 |
| Khan, SA | 1 |
| Ghayee, HK | 1 |
| Rege, J | 1 |
| Watumull, LM | 1 |
| Nwariaku, FE | 1 |
| Carrick, KS | 1 |
| Rainey, WE | 1 |
| Miller, WL | 1 |
| Auchus, RJ | 1 |
| Söndergaard, HP | 1 |
| Kushnir, MM | 1 |
| Aronsson, B | 1 |
| Sandstedt, P | 1 |
| Bergquist, J | 1 |
| SONKA, J | 2 |
| GREGOROVA, I | 1 |
| JIRANEK, M | 1 |
| KOELBEL, F | 1 |
| MATYS, Z | 1 |
| Dykes, PJ | 1 |
| Marks, R | 1 |
| Harper, PS | 1 |
| Hiroi, N | 1 |
| Yakushiji, F | 1 |
| Shimojo, M | 1 |
| Watanabe, S | 1 |
| Sugano, S | 1 |
| Yamaguchi, N | 1 |
| Miyachi, Y | 1 |
| Christiansen, P | 1 |
| Olofsson, BO | 1 |
| Grankvist, K | 1 |
| Boman, K | 1 |
| Forsberg, K | 1 |
| Lafvas, I | 1 |
| Lithner, F | 1 |
| Richards, GE | 1 |
| Cavallo, A | 1 |
| Meyer, WJ | 1 |
| Prince, MJ | 1 |
| Peters, EJ | 1 |
| Stuart, CA | 1 |
| Smith, ER | 1 |
| Graf, M | 1 |
| Distler, W | 1 |
| Schnürch, HG | 1 |
| Majewski, F | 1 |
| Matsumine, H | 1 |
| Holzmann, H | 1 |
| Krapp, R | 1 |
| Hoede, N | 1 |
| Morsches, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Selective Estrogen Receptor Modulators (SERMs) - A Potential New Treatment for Women of Child-bearing Age With Psychotic Symptoms of Schizophrenia[NCT02354001] | Phase 4 | 80 participants (Anticipated) | Interventional | 2011-04-30 | Completed | ||
| Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?[NCT00361543] | Phase 4 | 54 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Open-Label Vulvoscopy Photography Study of Changes in Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Administration of 6.5 Mg Vaginal Prasterone in Menopausal Women With Moderate to Severe Dyspareunia[NCT03568604] | Phase 4 | 18 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| A Review on the Clinical Outcome of Chinese Women With Moderate to Severe Symptoms of Genitourinary Syndrome of Menopause (GSM) Treated With Vaginal Dehydroepiandrosterone (DHEA)[NCT05434351] | 4 participants (Actual) | Observational | 2022-08-01 | Terminated (stopped due to inadequate sample and only few patients were prescribed with vaginal DHEA) | |||
| Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study)[NCT03740945] | Phase 3 | 0 participants (Actual) | Interventional | 2018-11-06 | Withdrawn (stopped due to Business decision to not perform this study.) | ||
| A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy[NCT03782480] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-03-02 | Recruiting | ||
| A Randomized, Double-blind, Placebo-controlled Trial on the Preventive Effect of Intravaginal Prasterone (DHEA, Intrarosa®) on Recurrent Urinary Tract Infections in Women With Genitourinary Syndrome of Menopause[NCT03854396] | Phase 3 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to due to termination of ISR by PI with agreement by grant sponsor) | ||
| [NCT02013544] | Phase 3 | 558 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Compare the Effectiveness and Side Effects of Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause[NCT05483634] | 40 participants (Anticipated) | Observational | 2022-10-28 | Not yet recruiting | |||
| Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.[NCT05585476] | 98 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | |||
| Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman: A Randomized Placebo-controlled Trial[NCT05627791] | Phase 2/Phase 3 | 6 participants (Actual) | Interventional | 2022-11-30 | Terminated (stopped due to Unable to recuit participant number in time.) | ||
| Photobiomodulation Effect on Vulvovaginal Atrophy in Postmenopausal Women: Randomized and Controlled Trial.[NCT04487392] | Phase 2 | 0 participants (Actual) | Interventional | 2020-12-15 | Withdrawn (stopped due to The student do not start the study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | Percentage of parabasal cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 54.25 | 12.74 | -41.51 |
| Placebo | 51.66 | 39.68 | -11.98 |
The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | Percentage of superficial cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 1.02 | 11.22 | 10.20 |
| Placebo | 1.04 | 2.78 | 1.75 |
The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.54 | 1.13 | -1.42 |
| Placebo | 2.56 | 1.50 | -1.06 |
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.75 | 2.03 | -0.73 |
| Placebo | 2.67 | 2.34 | -0.33 |
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.45 | 1.75 | -0.69 |
| Placebo | 2.43 | 2.06 | -0.37 |
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.83 | 2.09 | -0.74 |
| Placebo | 2.76 | 2.41 | -0.36 |
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.70 | 1.97 | -0.73 |
| Placebo | 2.63 | 2.24 | -0.39 |
The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.30 | 0.86 | -1.44 |
| Placebo | 2.30 | 1.13 | -1.17 |
A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 6.34 | 5.39 | -0.94 |
| Placebo | 6.32 | 6.05 | -0.27 |
6 reviews available for dehydroepiandrosterone and Syndrome
| Article | Year |
|---|---|
Current challenges in the pharmacological management of genitourinary syndrome of menopause.
Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of | 2023 |
Current challenges in the pharmacological management of genitourinary syndrome of menopause.
Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of | 2023 |
Current challenges in the pharmacological management of genitourinary syndrome of menopause.
Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of | 2023 |
Current challenges in the pharmacological management of genitourinary syndrome of menopause.
Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of | 2023 |
Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients.
Topics: Bayes Theorem; Dehydroepiandrosterone; Estrogens; Female; Female Urogenital Diseases; Humans; Laser | 2021 |
Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cancer Survivors; Dehydroepiandrosterone; Estrogens; Female; | 2019 |
A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial?
Topics: Aging; Dehydroepiandrosterone; Humans; Syndrome | 2013 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
[DEHYDROEPIANDROSTERONE DEFICIENCY A NEW SYNDROME?].
Topics: Dehydroepiandrosterone; Humans; Metabolic Diseases; Syndrome | 1965 |
3 trials available for dehydroepiandrosterone and Syndrome
14 other studies available for dehydroepiandrosterone and Syndrome
| Article | Year |
|---|---|
Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause.
Topics: Atrophy; Consensus; Dehydroepiandrosterone; Female; Female Urogenital Diseases; Humans; Menopause; S | 2022 |
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Topics: Administration, Intravaginal; Aged; Androgens; Atrophy; Consensus; Dehydroepiandrosterone; Dyspareun | 2018 |
Association between locomotive syndrome and blood parameters in Japanese middle-aged and elderly individuals: a cross-sectional study.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Biomarkers; Cross-Sectional Studies; Dehydroepiandrost | 2019 |
Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of the zona reticularis: a new syndrome.
Topics: Adrenal Glands; Adrenal Hyperplasia, Congenital; Adrenalectomy; Adult; Blotting, Western; Dehydroepi | 2011 |
Patterns of endogenous steroids in apathetic refugee children are compatible with long-term stress.
Topics: 17-alpha-Hydroxyprogesterone; Activities of Daily Living; Adolescent; Child; Chromatography, Liquid; | 2012 |
Syndrome of ichthyosis, hepatosplenomegaly and cerebellar degeneration--steroid sulphatase activity.
Topics: Cerebellar Diseases; Dehydroepiandrosterone; Fibroblasts; Hepatomegaly; Humans; Ichthyosis; Male; Sp | 1980 |
Human ACTH hypersensitivity syndrome associated with abnormalities of the ACTH receptor gene.
Topics: Adrenal Cortex Function Tests; Adrenocorticotropic Hormone; Aged; Aldosterone; Biomarkers; Corticotr | 1998 |
Urinary gonadotrophins in the Sertoli-Cell-only syndrome.
Topics: Adult; Androgens; Androsterone; Biological Assay; Biopsy; Castration; Dehydroepiandrosterone; Dexame | 1975 |
Dehydroepiandrosterone. Metabolic effects.
Topics: Adolescent; Adult; Androgens; Animals; Cell Division; Cell Membrane Permeability; Chemical Phenomena | 1976 |
Assessment of thyroid and adrenal function in patients with familial amyloidotic polyneuropathy.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Amyloidosis; Dehydroepiandros | 1989 |
Obesity, acanthosis nigricans, insulin resistance, and hyperandrogenemia: pediatric perspective and natural history.
Topics: Acanthosis Nigricans; Adolescent; Androstenedione; Body Weight; Child; Dehydroepiandrosterone; Femal | 1985 |
[Ovarian insufficiency in blepharophimosis, ptosis, epicanthus inversus].
Topics: Adult; Blepharoptosis; Chromosome Aberrations; Chromosome Disorders; Dehydroepiandrosterone; Eyelids | 1986 |
Accelerated conversion of androgen to estrogen in plasma-cell dyscrasia associated with polyneuropathy, anasarca, and skin pigmentation.
Topics: Adult; Androgens; Dehydroepiandrosterone; Edema; Estrogens; Female; Humans; Male; Paraproteinemias; | 1985 |
Exogenous and endogenous provocation of psoriasis. A contribution to the Koebner phenomenon.
Topics: Adolescent; Adult; Child; Cyclic AMP; Dehydroepiandrosterone; Female; Foodborne Diseases; Humans; In | 1974 |